VisEn Medical ( iniated a multiyear joint R&D program with Merck & Co. ( to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. It will focus on literature-derived and proprietary biomarkers of cardiovascular disease.
The program will use VisEn fluorescence agents and Fluorescence Molecular Tomography imaging systems. Agents developed will be used for measuring disease progression and therapeutic response in Merck’s discovery programs. VisEn says it further will commercialize the agents.

Next articleUMMZ Periodical Cicada Page